Discovering new biomarkers using Imaging Mass Cytometry
Biomarkers are currently used in research and in clinical practice, yet few are used to predict a clinical therapeutic outcome consistently and accurately. Particularly for cancer and other diseases with high tumor heterogeneity and broad cellular signatures, classification at an individual level is confounding. Imaging Mass Cytometry™ (IMC)™ can be used to uncover novel phenotypes and identify therapeutic targets that may be relevant to developing biomarkers and future treatment strategies.
Potential indicative immunotherapy biomarker in melanoma
Martinez-Morilla and colleagues demonstrated the use of IMC to quantitively measure 25 markers simultaneously to generate data from tumor, stroma, T cells, B cells and macrophages. Using IMC with biopsy samples from metastatic melanoma patients who received immunotherapy, the team discovered a compelling biomarker potentially indicative of treatment response in melanoma.
Answering key questions about the role of CAFs in lung cancer
In her webinar, Handan Xiang, PhD, describes how she and the team at Merck use IMC studies to understand cancer-associated fibroblasts in tumor stroma. Learn how this research illuminated a possible therapeutic path that could potentially reverse a CAF-mediated immunosuppressive microenvironment.
Novel signaling networks identified through IMC and transcriptomics data integration
The use of IMC enabled researchers to uncover the heterogeneity of cellular phenotypes and cell-to-cell interactions in the tumor microenvironment of high-grade serous ovarian cancer to understand which interactions might influence patient survival. Learn about the pipeline used to generate PhenoGraph clusters for cell density and neighborhood analysis along with correlating the IMC phenotype with a gene expression profile.
Unique expression signatures in Hodgkin lymphoma aid in the development of novel biomarkers
Scientists aim to unravel the very complex tumor microenvironment (TME) of Hodgkin lymphoma by deciphering the unique immune cell architecture of the TME and for the first time unveil its phenotype. They pair IMC with single-cell transcriptome analysis and suggest implications for the development of novel therapies, including rational combinations and predictive biomarker development.
Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices